Pregabalin vs placebo at end of treatment: Serious adverse events
- Population
- patients with fibromyalgia
- Intervention
- Pregabalin
- Comparison
- placebo at end of treatment
- Outcome
- Serious adverse events
Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Pregabalin vs placebo at end of treatment Serious adverse events · People with fibromyalgia Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty). Anticonvulsants for fibromyalgia (2013) · Cochrane Headline outcomes only | RR 1.03 [0.71, 1.49] | 4 studies · 2729 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Pregabalin vs placebo · adults with fibromyalgia enrolled in EERW studies · 1 review
- Pregabalin vs placebo · adults with fibromyalgia · 1 review
- Pregabalin vs placebo · children and adolescents with chronic non‐cancer pain · 1 review
- Pregabalin vs placebo · patients with chronic pancreatitis and pancreatic pain · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.